LEVETIRACETAM DEXCEL 500

Pajjiż: Iżrael

Lingwa: Ingliż

Sors: Ministry of Health

Ingredjent attiv:

LEVETIRACETAM

Disponibbli minn:

DEXCEL PHARMA TECHNOLOGIES LTD

Kodiċi ATC:

N03AX14

Għamla farmaċewtika:

TABLETS

Kompożizzjoni:

LEVETIRACETAM 500 MG

Rotta amministrattiva:

PER OS

Tip ta 'preskrizzjoni:

Required

Manifatturat minn:

DEXCEL LTD, ISRAEL

Grupp terapewtiku:

LEVETIRACETAM

Żona terapewtika:

LEVETIRACETAM

Indikazzjonijiet terapewtiċi:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Data ta 'l-awtorizzazzjoni:

2018-03-31